Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors.

[1]  B. Hoff,et al.  In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  M. K. Si,et al.  The origin and magnitude of intramolecular quasi-cyclic S⋯O and S⋯S interactions revisited: A computational study , 2015 .

[3]  B. Hoff,et al.  Truncated structures used in search for new lead compounds and in a retrospective analysis of thienopyrimidine-based EGFR inhibitors. , 2015, European journal of medicinal chemistry.

[4]  M. Cameron,et al.  Gauging reactive metabolites in drug-induced toxicity. , 2014, Current medicinal chemistry.

[5]  G. Bjørkøy,et al.  Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  M. Ihnat,et al.  The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. , 2014, Bioorganic & medicinal chemistry.

[7]  M. Moore,et al.  Assessing the role of the EGF receptor in the development and progression of pancreatic cancer , 2014 .

[8]  U. Nonstad,et al.  Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor. , 2014, European journal of medicinal chemistry.

[9]  H. Hassaneen,et al.  Phenacyl Bromides Revisited: Facile Synthesis of Some New Pyrazoles, Pyridazines, and Their Fused Derivatives , 2014 .

[10]  Huan-qiu Li,et al.  Epidermal growth factor receptor inhibitors: a patent review (2010 – present) , 2014, Expert opinion on therapeutic patents.

[11]  Jaiwook Park,et al.  Highly enantioselective enzymatic resolution of aromatic β-amino acid amides with Pd-catalyzed racemization , 2013 .

[12]  Michelle C. Schaeffer,et al.  Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. , 2013, ACS medicinal chemistry letters.

[13]  H. Hsieh,et al.  Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor. , 2013, Journal of medicinal chemistry.

[14]  P. Lyu,et al.  Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors. , 2013, Journal of medicinal chemistry.

[15]  Gur Pines,et al.  The ERBB network: at last, cancer therapy meets systems biology , 2012, Nature Reviews Cancer.

[16]  F. Serein-Spirau,et al.  Far-infrared spectroscopy investigation of sulfur–oxygen interactions in π-conjugated oligomers , 2012 .

[17]  J. Segall,et al.  Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling , 2012, Molecular medicine.

[18]  Cheng-Mei Zhang,et al.  Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds. , 2012, Anti-cancer agents in medicinal chemistry.

[19]  D. Brady,et al.  Enantioselective biocatalytic hydrolysis of β-aminonitriles to β-amino-amides using Rhodococcus rhodochrous ATCC BAA-870 , 2012 .

[20]  G. Bjørkøy,et al.  Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines. , 2011, European journal of medicinal chemistry.

[21]  Sing-Yi Wang,et al.  Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency. , 2010, Journal of medicinal chemistry.

[22]  H. Hsieh,et al.  Identification, SAR Studies, and X‐ray Co‐crystallographic Analysis of a Novel Furanopyrimidine Aurora Kinase A Inhibitor , 2010, ChemMedChem.

[23]  G. Mills,et al.  Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges , 2009, Journal of oncology.

[24]  Shohei Koide,et al.  The importance of being tyrosine: lessons in molecular recognition from minimalist synthetic binding proteins. , 2009, ACS chemical biology.

[25]  C. Peschel,et al.  Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy , 2009, Clinical Cancer Research.

[26]  J. Ahman,et al.  Development of a Bulk Enabling Route to Maraviroc (UK-427,857), a CCR-5 Receptor Antagonist , 2008 .

[27]  M. Rahimizadeh,et al.  One-Pot Synthesis of Substituted 2-Amino-3-Furonitriles , 2008 .

[28]  P. Graczyk.  Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. , 2007, Journal of medicinal chemistry.

[29]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[30]  Woody Sherman,et al.  Use of an Induced Fit Receptor Structure in Virtual Screening , 2006, Chemical biology & drug design.

[31]  Yutaka Maeda,et al.  Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[32]  L. Bubendorf,et al.  Expression patterns of potential therapeutic targets in prostate cancer , 2005, International journal of cancer.

[33]  J. Mestan,et al.  AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. , 2004, Cancer research.

[34]  G. Bold,et al.  Furo[2,3-d]pyrimidines and oxazolo[5,4-d]pyrimidines as inhibitors of receptor tyrosine kinases (RTK) , 2004 .

[35]  P. Furet,et al.  Pyrrolo[2,3-d]pyrimidine and Pyrazolo[3,4-d]pyrimidine Derivatives as Selective Inhibitors of the EGF Receptor Tyrosine Kinase , 2001 .

[36]  L. Gentilucci,et al.  A Stereoselective Synthesis of (2R,3S)-N-Benzoylphenylisoserine Methyl Ester , 1998 .

[37]  K. Yamagata,et al.  Studies on Heterocyclic Enaminonitriles. VI. Synthesis of 2-Amino-3-cyano-4, 5-dihydrofurans , 1985 .

[38]  G. Schroll,et al.  The Synthetic Utility of Heteroaromatic Azido Compounds. I. Preparation and Reduction of Some 3-Azido-2-substituted Furans, Thiophenes, and Selenophenes. , 1975 .

[39]  Nathalie Jurisch-Yaksi,et al.  Extended structure-activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties. , 2016, European journal of medicinal chemistry.

[40]  S. Mjåland,et al.  Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain–A case series , 2013, Scandinavian journal of pain.